Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LUMIGAN

« Back to Dashboard
Lumigan is a drug marketed by Allergan and is included in two NDAs. It is available from two suppliers. There are eleven patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-five patent family members in twenty-four countries.

The generic ingredient in LUMIGAN is bimatoprost. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. There are four tentative approvals for this compound. Additional details are available on the bimatoprost profile page.

Summary for Tradename: LUMIGAN

Patents:11
Applicants:1
NDAs:2
Suppliers: see list2

Pharmacology for Tradename: LUMIGAN

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Clinical Trials for: LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes5,688,819<disabled><disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes8,524,777<disabled><disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes8,278,353<disabled>Y<disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes8,772,338<disabled>Y<disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes8,299,118<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LUMIGAN

Drugname Dosage Strength RLD Submissiondate
bimatoprostOphthalmic Solution0.01%Lumigan4/5/2011
bimatoprostOphthalmic Solution0.03%Lumigan12/22/2008

Non-Orange Book Patents for Tradename: LUMIGAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,834,498 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents<disabled in preview>
5,352,708 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents<disabled in preview>
8,017,655Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents<disabled in preview>
6,204,287 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents<disabled in preview>
6,602,900 Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LUMIGAN

Country Document Number Publication Date
Australia2006227757Sep 28, 2006
European Patent Office1753434May 13, 2009
World Intellectual Property Organization (WIPO)9730710Aug 28, 1997
Spain2324058Jul 29, 2009
Canada2585691May 19, 2009
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc